Search results for "SKI"

showing 10 items of 9488 documents

Dermal CD207-Negative Migratory Dendritic Cells Are Fully Competent to Prime Protective, Skin Homing Cytotoxic T-Lymphocyte Responses

2018

Dendritic cells (DCs) are important inducers and regulators of T-cell responses. They are able to activate and modulate the differentiation of CD4+ and CD8+ T cells. In the skin, there are at least five phenotypically distinct DC subpopulations that can be distinguished by differential expression of the cell surface markers CD207, CD103, and CD11b. Previous studies have suggested that dermal CD11b−CD207+ conventional type 1 DCs are indispensable for the priming of a skin homing cytotoxic T-lymphocyte response. However, conventional type 1 DCs are also the only skin DC subset capable of cross-presenting exogenous antigens on major histocompatibility complex class I. Thus, it remained unclear…

0301 basic medicineLangerhans cellEpitopes T-LymphocytePriming (immunology)Mice TransgenicVaccinia virusDermatologyCD8-Positive T-LymphocytesBiologyMajor histocompatibility complexBiochemistryMice03 medical and health sciencesCross-Priming0302 clinical medicineAntigenmedicineAnimalsHumansCytotoxic T cellMolecular BiologySkinintegumentary systemCluster of differentiationHistocompatibility Antigens Class ICell BiologyDendritic cellCell biologyDisease Models Animal030104 developmental biologymedicine.anatomical_structureLangerhans Cells030220 oncology & carcinogenesisSkin Diseases Viralbiology.proteinImmunologic MemoryCD8T-Lymphocytes CytotoxicJournal of Investigative Dermatology
researchProduct

Effects of bingeing on fat during adolescence on the reinforcing effects of cocaine in adult male mice

2016

Binge eating is a specific form of overeating characterized by intermittent excessive eating. In addition to altering the neurobiological reward system, several studies have highlighted that consumption of palatable food increases vulnerability to drug use. The aim of the present study was to evaluate the effects of a high-fat diet consumed in a binge pattern during adolescence on the reinforcing effects of cocaine. After 40 days of binge-eating for 2 h, three days a week (PND 29–69), the reinforcing effects of cocaine on conditioning place preference and intravenous self-administration paradigm were evaluated in adolescent male mice. Circulating leptin and ghrelin levels and the effects of…

0301 basic medicineLeptinMalemedicine.medical_specialtyConditioning ClassicalDrug-Seeking BehaviorReceptors Opioid muGene ExpressionSelf AdministrationNucleus accumbensAnxietyDiet High-FatAdolescentsNucleus Accumbens03 medical and health sciencesCellular and Molecular NeuroscienceMice0302 clinical medicineCocaineReceptor Cannabinoid CB1RewardInternal medicinemedicineAnimalsOvereatingBulimiaPharmacologyBinge eatingdigestive oral and skin physiologyBody WeightVentral Tegmental AreaConditioned place preferenceGhrelinCocaïnaVentral tegmental areaAlimentació030104 developmental biologyEndocrinologymedicine.anatomical_structureGhrelinBrain stimulation rewardmedicine.symptomPsychologySelf-administrationCorticosterone030217 neurology & neurosurgery
researchProduct

Glucagon-like peptide-1 is associated with poor clinical outcome, lipopolysaccharide translocation and inflammation in patients undergoing cardiac su…

2020

International audience; Introduction: Cardiac surgery with cardiopulmonary bypass (CPB) is associated with gut barrier dysfunction. Gut barrier dysfunction might be estimated non-invasively by lipopolysaccharide (LPS) plasma concentration. Glucagon-like peptide-1 (GLP-1) is a gut secreted hormone that is a potential marker of mucosal integrity. Our objective was to evaluate GLP-1 as a peri-operative marker of gut barrier dysfunction in patients undergoing cardiac surgery with CPB.Methods: GLP-1, intestinal fatty acid binding protein (I-FABP) and lipopolysaccharide were assayed: at induction, after CPB and 24 h after admission in the intensive care unit. The primary end-point was peri-operat…

0301 basic medicineLipopolysaccharidesMaleLipopolysaccharideBiochemistryGastroenterologylaw.inventionchemistry.chemical_compound0302 clinical medicinelawGlucagon-Like Peptide 1Gut barrierImmunology and AllergyProspective StudiesCardiopulmonary Bypassdigestive oral and skin physiologyHematologyCardiac surgeryMiddle AgedCardiopulmonary by passIntensive care unitGlucagon-like peptide-1Digestive translocation3. Good healthCardiac surgeryGlucagon like peptid 1030220 oncology & carcinogenesisFemalemedicine.symptommedicine.medical_specialtyImmunologyInflammationLipopolysaccharide03 medical and health sciencesInternal medicineIntensive caremedicineCardiopulmonary bypassHumansCardiac Surgical ProceduresMolecular BiologyAgedInflammationbusiness.industryEndotoxemia030104 developmental biologychemistrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBiomarkersHormoneCytokine
researchProduct

Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.

2020

Abstract HER2-positive breast cancer is currently managed with chemotherapy in combination with specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients with HER2-positive tumors do not respond to trastuzumab (primary resistance) or either recur (acquired resistance), mostly due to molecular alterations in the tumor that are either unknown or undetermined in clinical practice. Those alterations may cause the tumor to be refractory to treatment with trastuzumab, promoting tumor proliferation and metastasis. Using continued exposure of a HER2-positive cell line to trastuzumab, we generated a model of acquired resistance characterized by increased expression …

0301 basic medicineMAPK/ERK pathwayCancer ResearchMAP Kinase Signaling SystemReceptor ErbB-2medicine.medical_treatmentMice NudeApoptosisBreast NeoplasmsCCL5Metastasis03 medical and health sciencesMice0302 clinical medicineBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabmedicineBiomarkers TumorTumor Cells CulturedGene silencingAnimalsHumansskin and connective tissue diseasesAutocrine signallingneoplasmsChemokine CCL5Neoadjuvant therapyCell Proliferationbusiness.industryGene Expression ProfilingTrastuzumabmedicine.diseaseXenograft Model Antitumor AssaysGene Expression Regulation NeoplasticAutocrine Communication030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchFemalebusinessmedicine.drugMolecular cancer therapeutics
researchProduct

Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling

2020

The epidermal growth factor receptor (EGFR) interacts with various downstream molecules including phospholipase C (PLC)/protein kinase C (PKC), Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/GSK-3, Jak/STAT and others. Often these pathways are deregulated in human malignancies such as breast cancer. Various therapeutic approaches to inhibit the activity of EGFR family members including small molecule inhibitors and monoclonal antibodies (MoAb) have been developed. A common problem with cancer treatments is the development of drug-resistance. We examined the effects of a conditionally-activated EGFR (v-Erb-B:ER) on the resistance of breast cancer cells to commonly used chemotherapeutic drugs such as doxorub…

0301 basic medicineMAPK/ERK pathwayEGFRvIIICancer ResearchEGFREstrogen receptorAntineoplastic AgentsBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerCell Line TumorGeneticsHumansMedicinePTENEpidermal growth factor receptorskin and connective tissue diseasesMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwaybiologybusiness.industryCancermedicine.diseaseErbB Receptors030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDrug resistancebiology.proteinCancer researchMolecular MedicineFemalebusinessSignal TransductionV-Erb-B
researchProduct

Expanding the clinical spectrum of mosaic BRAF skin phenotypes

2021

BRAF postzygotic activating mutations have been found in 50% of cases of syringocystadenoma papilliferum (SCAP)1 and in phacomatosis pigmentokeratotica (PPK)2,3 , also possibly caused by HRAS4 mutations. BRAF is a RAS-activating serine/threonine kinase of the MAP kinase pathway, resulting in cell growth and proliferation. BRAF mutations, particularly p.(Val600Glu), are frequently identified in melanoma and other human cancers5 . We report clinical presentations of three patients with postzygotic BRAF mutations in affected skin, identified by next generation sequencing (NGS).

0301 basic medicineMAPK/ERK pathwayProto-Oncogene Proteins B-rafendocrine system diseases[SDV]Life Sciences [q-bio]DermatologyDNA sequencingSerine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineThreonineneoplasmsComputingMilieux_MISCELLANEOUSSkinKinasebusiness.industryMelanomamedicine.diseasePhenotypedigestive system diseases3. Good health030104 developmental biologyInfectious DiseasesPhenotypeMutationCancer researchbusinessSyringocystadenoma papilliferum
researchProduct

Cytotoxicity of Labruscol, a New Resveratrol Dimer Produced by Grapevine Cell Suspensions, on Human Skin Melanoma Cancer Cell Line HT-144

2017

IF 2.861; International audience; A new resveratrol dimer (1) called labruscol, has been purified by centrifugal partition chromatography of a crude ethyl acetate stilbene extract obtained from elicited grapevine cell suspensions of Vitis labrusca L. cultured in a 14-liter stirred bioreactor. One dimensional (1D) and two dimensional (2D) nuclear magnetic resonance (NMR) analyses including ¹H, 13C, heteronuclear single-quantum correlation (HSQC), heteronuclear multiple bond correlation (HMBC), and correlation spectroscopy (COSY) as well as high-resolution electrospray ionisation mass spectrometry (HR-ESI-MS) were used to characterize this compound and to unambiguously identify it as a new st…

0301 basic medicineMagnetic Resonance SpectroscopySkin NeoplasmsCellPharmaceutical ScienceApoptosisResveratrolresveratrol[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyAnalytical Chemistry[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compoundbioreactor0302 clinical medicineBioreactorsDrug DiscoveryStilbenesVitisCytotoxicitylabruscolMolecular StructureChemistryCommunicationVitis labrusca L.Biological activity3. Good healthmedicine.anatomical_structureBiochemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineDimerizationCell Survivallcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryCell Line TumorPlant CellsfibroblastsmedicinemelanomaHumansViability assayPhysical and Theoretical Chemistrycytotoxic activityOrganic Chemistry[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyAntineoplastic Agents Phytogenic030104 developmental biologyApoptosisCell cultureFetal bovine serum
researchProduct

Cutaneous manifestations associated with anosmia, ageusia and enteritis in SARS-CoV-2 infection - a possible pattern? Observational study and review …

2021

BACKGROUND: The cutaneous manifestations of coronavirus disease 2019 (COVID-19) have been covered insufficiently in the literature. METHODS: Thirty-nine patients admitted to the study hospital with confirmed COVID-19 who experienced various skin manifestations during hospitalization or in the convalescence period, were analysed retrospectively. RESULTS: Thirty-nine patients with COVID-19, admitted to the study hospital between 23 March and 12 September 2020, had intra-infectious rash or lesions of cutaneous vasculitis during convalescence. The most common cutaneous manifestations of COVID-19 were erythematous and erythematous papular rash. Twenty-seven of the 39 patients had anosmia (69.2%)…

0301 basic medicineMaleACE2 angiotensin‐converting enzyme 2ErythemaReceptor expressionTNF Tumor Necrosis Factor alphaInfectious and parasitic diseasesRC109-216B cells B lymphocyteslesions0302 clinical medicine030212 general & internal medicineskin and connective tissue diseasesCOVID coronavirus disease 2019media_commonEnterocolitisNK cells Natural killer cellsConvalescenceGeneral MedicineRashEnteritisInfectious DiseasesFemalemedicine.symptomCD Cluster of differentiationIHC immunohistochemistryMicrobiology (medical)medicine.medical_specialtyRT real-time reverse transcriptase–polymerase chain reactionmedia_common.quotation_subjectAnosmia030106 microbiologyAnosmiaSkin DiseasesArticle03 medical and health sciencesmedicineHumansbiopsySARS Severe acute respiratory syndrome coronavirus 2HE Hematoxylin and eosin stainRetrospective Studiescutaneous manifestationsbusiness.industrySARS-CoV-2SARS-CoV-2 infectionCOVID-19Ageusiamedicine.diseaseDermatologyPneumoniaIL 1 Interleukin 1IFN-γ Interferon γbusinessAgeusiaInternational Journal of Infectious Diseases
researchProduct

Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.

2016

Abstract Background Adalimumab is effective in the treatment of Crohn's disease. We have already reported data on the efficacy of adalimumab in 110 steroid-dependent patients. At the end of the study 90 patients (64.5%) maintained clinical remission. Aims To assess efficacy and safety of adalimumab after 6 years in patients of the original cohort who responded to treatment. Methods The present study is an extension of the published paper on 90/110 patients. We report results on clinical remission and safety of 6 year maintenance therapy with adalimumab. Results Of the original cohort 90 patients completed the study, 17 were lost to follow-up and 3 died. At the end of follow-up (74.16 ± 10.3…

0301 basic medicineMaleAnti-Inflammatory AgentsKaplan-Meier EstimateSingle CenterInflammatory bowel diseaseInflammatory bowel disease0302 clinical medicineMaintenance therapyCrohn DiseaseLong term therapyProspective Studiesskin and connective tissue diseasesProspective cohort studyMultivariate AnalysiCrohn's diseaseRemission InductionGastroenterologyMiddle AgedCrohn's diseaseAnti-Inflammatory AgentTreatment OutcomeItalyCohort030211 gastroenterology & hepatologyFemaleSteroidsHumanmedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtySteroid dependencyMaintenance Chemotherapy03 medical and health sciencesInternal medicinemedicineAdalimumabHumansAdverse effectSteroidHepatologybusiness.industryAdalimumabmedicine.diseaseSurgeryProspective Studie030104 developmental biologyMultivariate AnalysisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.

2019

The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. ispartof: EUROPEAN JOURNAL OF CANCER vol:124 pages:67-…

0301 basic medicineMaleCancer ResearchEsophageal NeoplasmsADJUVANT CHEMOTHERAPY0302 clinical medicineEUROPEAN ORGANIZATIONMultidisciplinary approachGastricPerioperativeStage (cooking)AdjuvantClinical OncologyMISMATCH REPAIR DEFICIENCYdigestive oral and skin physiologyGastro oesophageal junctionOPEN-LABELPrognosisJCOGhumanitiesEORTCOncology030220 oncology & carcinogenesisCLINICAL-RESEARCHFemaleImmunotherapyEsophagogastric JunctionRANDOMIZED PHASE-IILife Sciences & Biomedicinemedicine.medical_specialtyStage ii03 medical and health sciencesStomach NeoplasmsmedicineChemotherapyHumansNeoplasm StagingScience & Technologybusiness.industryPERIOPERATIVE CHEMOTHERAPYGeneral surgeryCancerADENOCARCINOMAPLUS OXALIPLATINmedicine.diseaseSurvival Analysisdigestive system diseases030104 developmental biologyNeoplasm stagingbusinessTRIAL DESIGNEuropean journal of cancer (Oxford, England : 1990)
researchProduct